Slide 1: Q3 and YTD 2021 Sales Update
Ronny Living with neuroendocrine tumors Ringwood, UK Q3 and YTD 2021 Sales Update 21 October 2021 1
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor • This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements
Slide 3: Speakers
Speakers David Loew Aymeric Le Chatelier Chief Executive Officer Chief Financial Officer 3
Slide 4: Headlines: Further top-line growth; strategic progress continues
Headlines Further top-line growth; strategic progress continues Total sales Palovarotene regulatory update • YTD 2021: +12.3% to €2,078m • Withdrawal of NDA in the U.S. and • Q3 2021: +14.9% to €727m clock-stop in the EU • Anticipated US FDA resubmission in H1 2022 COVID-19 External-innovation advan
Slide 5: YTD 2021 sales: strong growth of key medicines – Oncology
YTD 2021 sales: strong growth of key medicines Oncology +11.0% +8.5% • Continued share growth in most markets • A limited impact from generic SSAs €1,565m: 75% of total sales +15.9% €m 93 • Good result driven by recovery in China 90 259 • Further market-share gains elsewhere 214 333 +21.6% 288 • Str
Slide 6: YTD 2021 sales: strong growth of key medicines – Neuroscience
YTD 2021 sales: strong growth of key medicines Neuroscience +25.1% €310m: 15% of total sales • +24.0% to €305m €m • Q3 2021 sales growth +18.2%: structural growth, with a reducing benefit from the pandemic comparative 310 258 • Good performances in the North America and Europe therapeutics markets •
Slide 7: YTD 2021 sales: strong growth of key medicines – Consumer Healthcare
YTD 2021 sales: strong growth of key medicines Consumer Healthcare +9.8% €165m: 8% of total sales €m Other • A strong performance, driven by improving 22 20 post-COVID 19 conditions in China 26 Fortrans®/ 19 Eziclen® 27 28 Tanakan® • Good Smecta OTC sales, offset by generic 30 26 Forlax® competition
Slide 8: Advancing external innovation
Advancing external innovation Oncology Neuroscience Accent Therapeutics: METTL3 Exicure: Spherical Nucleic Acids • Exclusive worldwide collaboration: targeting • Exclusive options: Huntington’s disease and the RNA modifying protein, METTL3 Angelman syndrome • Stage: preclinical • Stage: preclinical
Slide 9: Strengthening the pipeline
Strengthening the pipeline Phase I Phase II Phase III Registration Cabometyx + atezolizumab IPN601301 Cabometyx + atezolizumab Cabometyx Solid tumors FOP 1L HCC 2L RR DTC4 IPN59011 NEW mesdopetam Cabometyx + atezolizumab palovarotene Longer-acting neurotoxin PD-LID 2L NSCLC2 FOP Ax IPN10200 Longer-a
Slide 10: Upgraded FY 2021 guidance
Upgraded FY 2021 guidance Total sales growth1 Unchanged expected adverse impact of around 2% from currencies based on the level of exchange rates greater than +11.0% at the end of September 2021 Core operating margin2 Including impact from external-innovation transactions around 34% finalized to dat
Slide 11: A strategy continuing to deliver strong growth
A strategy continuing to deliver strong growth Maximize Strengthen our brands pipeline Drive Focus on efficiencies culture 11
Slide 12: Q&A
Liu Gang Living with acromegaly Beijing, China Q&A 12
Slide 13: Appendix
APPENDIX 13
Slide 14: Strong & expanding global footprint
Strong & expanding global footprint North America EU5 Rest of World 31% 32% 37% of total sales of total sales of total sales countries where countries with 30+ Ipsen presence 115+ Ipsen medicines are marketed Based on total sales in the first nine months of 2021. EU5: France, Germany, Italy, Spain a
Slide 15: YTD 2021: total-sales breakdown
YTD 2021: total-sales breakdown Specialty Care Consumer Healthcare Total Sales: €1,912m Total Sales: €165m €m +12.5% €m +9.8% +11.9% +8.5% Specialty Care €2,381.1m +5.9%1 +8.7% 64 -12.9% +40.6% 874 +15.9% +10.7% +24.0% +21.6% +10.4% -11.9% -10.1% 28 26 26 333 305 22 259 93 25 13 Smecta Tanakan Forla
Slide 16: YTD 2021 total-sales performance adversely impacted by foreign-exchange rates
YTD 2021 total-sales performance adversely impacted by foreign-exchange rates Average rate changes YTD 2021 sales by currency (YTD 2021 vs. 2020) 2% USD: 1.20 Other1 16% -6% RUB 3% EUR -11% -12% CNY 5% 39% -14% GBP 5% -28% 32% USD RUB TRY BRL DZD CNY USD Adverse 3.0% impact: lower USD, RUB, TRY and
Slide 17: Oncology: Key ongoing clinical-trial highlights
Oncology Key ongoing clinical-trial highlights Trial Population Patients Design Endpoints Status PFS primary endpoint met. Interim OS Sorafenib Cabometyx® primary endpoint not or Primary: PFS, OS COSMIC 312 met 1L HCC 740 Cabometyx + atezolizumab Secondary: PFS single-agent Phase III or Cabometyx ar
Slide 18: Oncology: Key ongoing clinical-trial highlights
Oncology Key ongoing clinical-trial highlights Trial Population Patients Design Endpoints Status Second novel hormonal Recruiting Cabometyx® Primary: OS, PFS therapy (abiraterone and CONTACT-02 Additional endpoints: ORR, 2L mCRPC 580 prednisone or enzalutamide) Data readout Phase III prostate-specif
Slide 19: Neuroscience: Key ongoing clinical-trial highlights
Neuroscience Key ongoing clinical-trial highlights Trial Population Patients Design Endpoints Status Interventional post-marketing Primary: safety Dysport Adult patients with double-blind crossover, (noninferiority) Phase IV 564 Recruiting upper limb spasticity Dysport vs Secondary: efficacy NCT0493
Slide 20: Rare Disease: Key ongoing clinical-trial highlights
Rare Disease Key ongoing clinical-trial highlights Trial Population Patients Design Endpoints Status Active, not recruiting Primary: annualized change in Palovarotene Palovarotene - 5mg QD and new HO volume US FDA resubmission MOVE FOP upon flare-up, 20mg QD for Secondary: subjects with new anticipa
Slide 21: Investor Relations contacts
Craig Marks Vice President, Investor Relations +44 7564 349 193 craig.marks@ipsen.com Adrien Dupin de Saint-Cyr Investor Relations Manager +33 6 64 26 17 49 adrien.dupin.de.saint.cyr@ipsen.com 21
Slide 22: Q3 and YTD 2021 Sales Update
Ronny Living with neuroendocrine tumors Ringwood, UK Q3 and YTD 2021 Sales Update 21 October 2021 22